

M. COTTINI<sup>1</sup>, R. ASERO<sup>2</sup>

# Asthma phenotypes today

<sup>1</sup>Specialista in Allergologia e Immunologia Clinica, Specialista Malattie Apparato Respiratorio, Bergamo, Italia

<sup>2</sup>Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italia - r.asero@libero.it

## KEY WORDS

*Asthma, eosinophils, neutrophils, bronchial hyperresponsiveness, corticosteroids, therapy*

## Corresponding author

Marcello Cottini, MD  
Via Borgo Palazzo 116  
Bergamo

## SUMMARY

*PubMed databases were searched for articles regarding asthma phenotypes. Asthma has long been recognized as a heterogeneous disease, with hallmark features including age of onset, pattern of severity and other clinical characteristics, but recently it is no longer considered as single disease but rather as a series of complex, overlapping individual phenotypes, and a novel classification of the disease according to the nature of the underlying airway inflammation has been suggested. It has become increasingly clear that asthma is a complex syndrome. Recognition of specific subphenotypes may improve our understanding of underlying genetic basis and of pathophysiologic mechanisms as well as of response to treatment.*

## Definition

***“Phenotype: the visible characteristics of an organism resulting from the interaction between its genetic makeup and environment” (1)***

Asthma is a common airway disorder that is characterized by the presence of chronic inflammation, resulting in air-flow obstruction and bronchial hyperresponsiveness that causes wheezing, coughing, and dyspnea (2). Asthma impacts significantly on the rising burden of chronic disease in developed countries; approximately 5 to 10% of patients have a refractory disease, that remains poorly controlled despite maximal inhaled therapy (3). Asthma, like many chronic disorders, is a genetically complex disease; many genes (>100 have been identified) are likely to contribute to its different manifestations. Although asthma has long been recognized as a heterogeneous disease (4, 5), only in recent years it is seen not as single disease but rather as a series of complex, overlapping individual phe-

notypes, each defined by its unique interaction between genetic and environmental factors (6). A precise definition of asthma phenotypes is becoming increasingly important, because recognition of specific subphenotypes may further improve our understanding of underlying genetic basis, pathophysiologic mechanisms, treatment response and prognosis.

## Classification

In 2006, Wenzel (7) proposed that the different asthma phenotypes were partly dependent on different disease processes in each individual; adult phenotypes of asthma were therefore subdivided into three basic categories (7):

### *Clinical or physiological phenotypes*

- Severity-defined
- Exacerbation-prone
- Defined by chronic restriction

- Treatment-resistant
- Defined by age at onset

*Phenotypes related to the following triggers*

- Aspirin or on-steroidal anti-inflammatory drugs
- Environmental allergens
- Occupational allergens or irritants
- Menses
- Exercise


*Inflammatory phenotypes*

- Eosinophilic
- Neutrophilic
- Pauci-granulocytic

Adapted from Wenzel (7).

There may be overlap between phenotypes, and they may change over time (Fig. 1)

**Figure 1** - Venn diagram of phenotypes of childhood and adult-onset asthma. Adapted from Wenzel (7)



*Early onset asthma*

The age of onset differentiates asthma phenotypes because patients with early-onset asthma (onset before 12 years of age) show a significantly greater likelihood of having allergic sensitization than patients with late-onset disease (8). Additionally, patients with early-onset asthma are much more likely to have a history of eczema and a family history of asthma (8). Recent studies seem to show an association between some genetic polymorphisms and early-onset asthma (9) and intrauterine exposures causing epigenetic regulation may also affect asthma risk (10). Despite a longer duration of disease and a increased susceptibility to frequent exacerbations (7), people with early-onset asthma were shown to have better lung function than those with late-onset disease (11). The allergic phenotype shows a good response to inhaled corticosteroids (12) and, when indicated (asthma mild to moderate, coexistence of allergic rhinitis), to allergen immunotherapy, one of the best examples of phenotype-oriented therapeutic approach and, still today, the only potentially disease-modifying therapy (13); the long-lasting and preventive effects of specific immunotherapy should be taken into account when the efficacy is evaluated (14). In allergic asthma, treatment guidelines now recommend omalizumab (a recombinant humanized monoclonal anti-IgE antibody that binds to the Fc-region of the IgE molecule) as add-on option for patients with moderate-to-severe disease uncontrolled on high-dose inhaled corticosteroids and long-acting  $\beta$ -agonists (15). Omalizumab is well-tolerated and, in patients (children and adults) with uncontrolled allergic asthma, significantly improves pulmonary function and quality of life, and decreases clinical symptoms (16-19).

*Adult-onset asthma*

Adult-onset asthma is a subtype of asthma characterized by a significantly lower likelihood of allergic sensitization, female predominance, higher degree of severity, more frequent association with nasal polyposis (20) and different genetic background (21). In adult-onset asthma, some patients present with marked airflow restriction, probably related to airway inflammation and remodeling, and with a faster decline in forced expiratory volume in 1 second ( $FEV_1$ ), compared with nonasthmatic subjects (22-24). Lee et al. (22) examined demographic and clinical characteristics associated with persistent airflow limitation (Table 1).

**Table 1** - Risk factors independently associated with persistent airflow limitation in asthma

- Adult onset
- Male sex
- African American ethnicity
- Nonallergic (intrinsic) asthma
- Genetic predisposition (eg, ADAM33)
- Smoking history
- Aspirin intolerance (AERD)
- Some phenotypes of occupational asthma
- Poor airway function shortly after birth

Adapted from Lee et al. (22)

### *Aspirin-exacerbated asthma*

Asthma that is exacerbated by aspirin, also referred to as Aspirin-Exacerbated Respiratory Disease (AERD), is associated with adult-onset disease, and represents a distinct clinical syndrome characterized by chronic hyperplastic rhinosinusitis, nasal polyps, and asthma attacks after ingestion of aspirin and other nonsteroidal antiinflammatory drugs. Aspirin-sensitive asthma is associated with little evidence of atopy, raised airway leukotrienes, and high numbers of eosinophils in both tissue and blood (Table 2).

The prevalence of AERD in adult asthmatic populations is approximately 10% to 20%, but increases to 30% to 40% when asthma is associated with chronic hyperplastic sinusitis and nasal polyposis (25-27). This asthma phenotype is frequently poorly responsive to inhaled steroids,

**Table 2** - Clinical features of aspirin-exacerbated respiratory disease

- Adult onset
- Female predominance
- Asthma that is usually moderate to severe
- Chronic hyperplastic eosinophilic sinusitis (usually moderate to severe)
- Anosmia
- Nasal polyps
- Tissue and circulating eosinophilia
- Sensitivity to aspirin and nonselective (cyclooxygenase-1 inhibiting) nonsteroidal anti-inflammatory drugs
- Overproduction and overresponsiveness to cysteinyl leukotrienes
- Atopy typically not present

Adapted from Borish L et al. (6)

and is therefore present most often in patients with severe asthma. The association with raised leukotrienes predicts a good response to drugs that modify leukotriene pathways (28, 29), but not all patients respond. Although this phenotype is very distinct clinically and pathologically, the underlying pathogenesis remains poorly understood (30).

### **Asthma inflammation and its subphenotypes**

Since the introduction of noninvasive procedures to estimate airway inflammation in asthma, the recognition of inflammatory subphenotypes based on the pattern of airway inflammation seems particularly useful in increasing our understanding of the disease; moreover, the identification of inflammatory subphenotypes can assist clinicians in management of individual patients.

### *Eosinophilic asthma*

Eosinophilic asthma is the best studied pathological phenotype; eosinophils have been reported in sputum, lavage and endobronchial biopsies of many people with asthma (around 50% of patients have eosinophilic involvement) (31-34), but some studies suggest that eosinophilic inflammation might be present in a greater proportion of asthmatic patients than previously believed, since this inflammation could be predominant in a distal portion of the lung, not assessed by standard methods (35, 36). Eosinophilic inflammation, measured by sputum eosinophil count, increases with asthma severity (37). Patients with eosinophilic asthma have a significantly increased short term response to inhaled corticosteroids than those with non-eosinophilic asthma (38). Sputum eosinophil count and exhaled nitric oxide levels are predictors of clinical response to corticosteroids (39, 40); however sputum eosinophils and elevated levels of eosinophil cationic protein often persist in asthma patients despite ICS therapy, particularly in severe disease (32). Eosinophilic airway inflammation appears to be closely related to the risk of severe asthma exacerbations (41). Persistent eosinophilic inflammation in severe asthma is often associated with adult-onset disease, and with aspirin sensitivity (8). The eosinophil phenotype in severe asthma may persist over a 5-year period (42). In patients with uncontrolled asthma, two studies have shown that treatment with mepolizumab, an anti-interleukin-5 monoclonal antibody, can significantly reduce sputum eosino-

philia, the number of exacerbations and can improve the quality of life (43, 44); these data indicate the importance of a correct phenotyping of refractory eosinophilic asthma. An asthma subphenotype associated with a high type 2 helper T-cell (Th2) phenotype has been recently described (45). This high-Th2 phenotype has been defined as an IgE level greater than 100 ng per milliliter and more than  $0.14 \times 10^9$  eosinophils per liter in the peripheral blood (45). In patients with asthma, the high-Th2 phenotype has been associated with an increase in circulating periostin, a matricellular protein induced by interleukin-13 and expressed by airway structural cells. Recently, Corren and colleagues reported the effects of an interleukin-13 inhibitor, lebrikizumab, in a cohort of patients with moderate asthma who were symptomatic despite taking inhaled glucocorticoids and, in most cases, an additional long-acting beta-agonist (46). Although there was an effect on airflow obstruction in all the patients who were treated with lebrikizumab, the effect was greater in patients who had circulating levels of periostin above the median and exhibited the high-Th2 phenotype than in those without this phenotype. These data provide a proof of concept that asthma therapy can be targeted to susceptible patients.

#### *Noneosinophilic asthma*

The use of induced sputum (47), along with bronchoscopy studies of patients with severe asthma (32), have clearly demonstrated that eosinophilic inflammation is not universally present, with noneosinophilic asthma further divided into neutrophilic and pauci-granulocytic phenotypes (32, 33). Neutrophilic asthma may be present either alone or in conjunction with eosinophilic inflammation (49). According to some studies, this inflammatory phenotype may account for as many as 50% of adult-onset asthma cases (49) and for the majority of non-allergic asthmatic children (50). In adults, neutrophilic asthma is seen most commonly in females (51), especially in obese (52) and in women with menopausal asthma (53). Neutrophilic asthma phenotype is associated with more severe disease (54) and has been reported in autopsies of patients who died soon after the onset of a severe exacerbation (55, 56), but noneosinophilic inflammation has also been confirmed in patients with milder disease (51). Noneosinophilic patients are less likely to be atopic (51). The cause of neutrophilic inflammation is unknown but may involve multiple factors, such as environmental (sometimes occupa-

tional) exposure to bacterial endotoxin, bacterial biofilms, particulate air pollution, cigarette smoke, infections (viruses and intracellular pathogens, especially chlamydial respiratory infection) (31). In the pathogenesis innate immunity, oxidative stress and Th1/Th17 responses are involved (57). Corticosteroids are generally less effective in neutrophilic than in eosinophilic inflammation<sup>7</sup>, and, paradoxically, may promote neutrophilic asthma by inhibiting neutrophil apoptosis (7, 58). Noneosinophilic asthma is associated with a reduced short-term and long-term response to corticosteroid therapy (36), and the absence of a steroid response is predicted by baseline exhaled nitric oxide (59). Anti-neutrophilic therapies have not been systematically studied yet; there is some evidence that long-acting  $\beta_2$ -agonists, in contrast with corticosteroids, inhibit neutrophilic inflammation in the airways (60, 61). These results may explain why combination inhalers containing a long-acting  $\beta_2$ -agonist and a corticosteroid can be more effective in treating asthma, as they target not only eosinophilic but also neutrophilic inflammation (62). Recent studies have shown that once-daily tiotropium provides useful additional bronchodilatation when added to a LABA in some patients with severe asthma (63, 64); moreover a noneosinophilic sputum profile is associated with a better response (65). Theophylline may be useful in treating neutrophilic asthma and reversing corticosteroid resistance in patients with severe disease and in smokers. The mechanism whereby theophylline reverses corticosteroid resistance is currently being explored, but it is known that this is not mediated via inhibition of phosphodiesterases (PDEs) (62). Roflumilast, a selective PDE4 inhibitor, is currently licensed for use in patients with severe COPD, and therefore there has been increased interest in its potential for the treatment of severe noneosinophilic asthma. Roflumilast increases lung function in patients with mild to moderate asthma, an effect that is comparable to a low dose of inhaled corticosteroids (66). It has long been recognized that macrolides have anti-inflammatory effects that might be independent of their antibiotic effects (67). In patients with severe neutrophilic asthma, a course of clarithromycin significantly reduced sputum neutrophil numbers and CXCL8 concentrations, with some improvement in symptoms (68). Recently, Montelukast, a cysteinyl leukotriene receptor antagonist, showed secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of CysLT1Rs. These novel activities enable montelukast to target eosinophils, monocytes,

and, in particular, the corticosteroid-insensitive neutrophil (69). In a recent study, montelukast and formoterol showed interactive inhibitory effects on activated human neutrophils; these findings may explain the efficacy of montelukast and LABA when used in combination with inhaled corticosteroids in the treatment of severe asthma, possibly by controlling neutrophil-driven inflammation of the airways (70). Several uncontrolled or small studies suggested that anti-TNF therapies (TNF blocking antibodies infliximab or soluble receptor etanercept) might be useful in reducing symptoms, exacerbations, and airway hyperresponsiveness in patients with severe asthma (71, 72), but a recent large multicenter trial with the humanized antibody golimumab showed no beneficial effect on lung function, symptoms, or exacerbations, and there were increased reports of pneumonia and cancer (73).

## Endotypes


Although phenotypes are usually clinically relevant, they do not necessarily relate to the underlying disease processes. Recently, a different classification of disease entities within the asthma syndrome was proposed, whereby asthma is divided into distinct disease entities with specific mechanisms, called “asthma endotypes.” While phenotypes rely on observable characteristics, endotypes relate to the underlying functional or pathological mechanisms. As such, endotypes are distinct disease entities, not equivalent to phenotypes, but which may be present within clusters of phenotypes (74). Using these criteria, a PRACTALL (PRACTical ALLergy) consensus report produced by experts from the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology, was able to identify several asthma endotypes (Fig. 2) (75).

The authors selected 7 parameters (clinical characteristics, biomarkers, lung physiology, genetics, histopathology, epidemiology, and treatment response) to define an endotype and each endotype should fulfill at least 5 of the 7 parameters; asthma phenotypes can be present in more than 1 endotype, and endotypes can contain more than 1 phenotype.

### *Proposed endotypes*

- Aspirin sensitive Asthma
- ABPM (Allergic bronchopulmonary mycosis)
- Allergic asthma (adults)

**Figure 2** - Asthma is made up of different endotypes. Adapted from Lotvall et al. (75)



- API (asthma-predictive indices)-positive preschool wheezer
  - Severe late-onset hypereosinophilic
  - Asthma in cross-country skiers
- Adapted from Lotvall et al. (75).

Even severe asthma can present in multiple different phenotypes, and initial studies have been identified at least four endotypes (75):

- Severe early-onset allergic asthma
  - Adult-onset, persistently eosinophilic severe asthma
  - ABPM (Allergic bronchopulmonary mycosis)
  - Late-onset, obese, female, less eosinophilic
- Adapted from Wenzel (76).

The last endotype includes a group of symptomatic older women, generally with adult-onset disease and a high BMI. This phenotype was observed in UK and USA clusters (77, 78). Obese patients show very symptomatic disease, despite preserved lung function. Allergy does not appear to be associated with this endotype and in the European cohort there was little evidence for inflammation (78). With regard to the response to therapy, there is an association between increased BMI and reduced therapeutic effect of ICS-containing regimens (79). Weight reduction in obese patients with asthma improves lung function, symptoms, morbidity, and health status (80). Patients who lost weight following bariatric surgery improved markedly asthma symptoms, lung function and quality of life (81).

## Conclusion

In conclusion, it has become increasingly clear that asthma is a complex syndrome. To improve our understanding of asthma, it will be necessary to classify patients according to the underlying disease mechanism rather than clinical characteristics. The classification of patients with asthma by phenotype/endotype will facilitate future research to test novel therapeutic targets and endotype-specific treatments.

## References

1. The Encarta World Dictionary. New York: St Martin's Press; 1999.
2. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma- Summary Report 2007. *J Allergy Clin Immunol* 2007; 120 (5 suppl): S94-S138.
3. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. *Lancet* 2006; 368: 780-93.
4. Rackemann FM. A clinical classification of asthma. *Am J Med Sci* 1921; 12: 802-3.
5. Martinez F. Asthma and Wheezing in the first Six Years of Life. *N Eng J Med* 1995.
6. Borish L. Asthma : a syndrome composed of heterogeneous diseases. *Ann Allergy Asthma Immunol* 2008; 101: 1-9.
7. Wenzel SE. Asthma: defining of the persistent adult phenotypes. *Lancet*. 2006;368:804-813
8. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. *J Allergy Clin Immunol* 2004; 113: 101-8.
9. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. *N Eng J Med* 6; 359 (19):1985-94.
10. Kuriakose JS, Miller RL. Environmental epigenetics and allergic diseases: recent advances. *Clinical & Experimental Allergy*, 2010.
11. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. *Am J Respir Crit Care Med* 2001; 164: 744-8.
12. de Marco R, Marcon A, Jarvis Det al. Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. *J Allergy Clin Immunol* 2007; 119 (3): 611-7.
13. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. *Curr Opin Allergy Clin Immunol* 2011; 11 (6): 586-93.
14. Passalacqua G. Specific immunotherapy: beyond the clinical scores. *Ann Allergy Asthma Immunol* 2011; 107 (5): 401-6.
15. Global Strategy for Asthma Management and Prevention 2011 (update). [www.ginasthma.org](http://www.ginasthma.org)
16. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. *N Engl J Med* 2011; 364: 1005-15.
17. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy* 2004; 34: 632-8.
18. Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Respir J* 2002; 20: 1088-94.
19. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. *Clinical & Experimental Allergy* 2009; 39: 788-97.
20. Bel EH. Clinical phenotypes of asthma. *Curr Opin Pulm Med* 2004; 10: 44-50.
21. Hizawa N, Yamaguchi E, Konno S, et al. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. *Am J Respir Crit Care Med* 2002; 166: 686-90.
22. Lee JH, Haselkorn T, Borish L et al. Risk factors associated with persistent airflow limitation in severe or difficult to-treat asthma: insights from the TENOR Study. *Chest* 2007; 132: 1882-9.
23. Kaminska M, Foley S, Maghni K et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. *J Allergy Clin Immunol* 2009; 124: 45-51.
24. ten Brinke A. Risk factors associated with irreversible airflow limitation in asthma. *Curr Opin Allergy Clin Immunol* 2008; 8 (1): 63-9.
25. Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. *J Allergy Clin Immunol* 2005; 116: 970-5.
26. Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. *Curr Allergy Asthma Rep* 2004; 4: 17-24.
27. Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. *Clin Rev Allergy Immunol* 2003; 24: 113-24.
28. Gaber F, Daham K, Higashi A. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. *Thorax* 2008; 63: 1076-1082.
29. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist. *Am J Respir Crit Care Med* 2002; 165.
30. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. *J Allergy Clin Immunol* 2003; 111: 913-21.
31. Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: Relationship to bronchial hyperreactivity. *Am Rev Respir Dis* 1988; 137: 62-9.
31. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. *Thorax* 2002; 57: 643-8.
32. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med* 1999; 160: 1001-8.
33. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. *Curr Opin Allergy Clin Immunol* 2007; 7: 43-50.
34. Bousquet J, Chanez P, et al. Eosinophilic inflammation in asthma. *N Engl J Med* 1990; 323: 1033-9.
35. Balkissoon RC, Balzar S, Rhodes D, et al. Eosinophils persist in the distal lung of severe asthma despite low numbers in proximal

- airways American Thoracic Society Annual Meeting, San Diego, CA, USA, 2006. A15.
36. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. *Eur Respir J* 2005; 25: 986-91.
  37. Louis R, Lau LC, Brown A, et al. The relationship between airways inflammation and asthma severity. *Am J Respir Crit Care Med* 2000; 161: 9-16.
  38. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. *Thorax* 2007; 62 (12): 1043-9.
  39. Meijer RP, Postma DS, Kauffman HF, et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. *Clin Exp Allergy* 2002; 32 (7): 1096-103.
  40. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011; 184 (5): 602-15.
  41. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. *Eur Respir J* 2006; 27: 483-94.
  42. van Veen HP, ten Brinke A, Gauw SA, et al. Persistent sputum eosinophilia in patients with severe asthma: a 5-year follow-up study. American Thoracic Society Annual Meeting, San Diego, CA, USA 2005. A241
  43. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009; 360 (10): 973-84.
  44. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. *N Engl J Med* 2009; 360 (10): 985-93.
  45. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med* 2009; 180: 388-95.
  46. Corren J, Lemanske RF Jr, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. *N Engl J Med* 2011; 365: 1088-98.
  47. Simpson JL, Scott R, Boyle MJ et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. *Respirology* 2006; 11: 54-61.
  48. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. *Chest* 2001; 119: 1329-36.
  49. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. *Thorax* 2002; 57: 643-8.
  50. Drews AC, Pizzichini MM, Pizzichini E, et al. Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children. *Allergy* 2009; 64: 1597-601.
  51. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. *Thorax* 2002; 57: 875-9.
  52. Scott HA, Gibson PG, Garg ML et al. Airway inflammation is augmented by obesity and fatty acids in asthma. *Eur Respir J* 2011; 38 (3): 594-602.
  53. Foschino-Barbaro MP, Costa VR, Resta O, et al. Menopausal asthma: a new biological phenotype? *Allergy* 2010.
  54. Wenzel SE, Szefler SJ, Leung DYM, et al. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. *Am J Respir Crit Care Med* 1997; 156: 737-43.
  55. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma—a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? *Am Rev Respir Dis* 1993; 148: 713-9.
  56. James AL, Elliot JG, Abramson MJ, et al. Time to death, airway wall inflammation and remodelling in fatal asthma. *Eur Respir J* 2005; 26: 429-34.
  57. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma. *Thorax* 2007; 62: 211-8.
  58. Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. *Apoptosis* 2003; 8: 481-95.
  59. Cowan DC, Cowan JO, Palmay R et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. *Thorax* 2010; 65: 384-90.
  60. Jeffery PK, Venge P, Gizycki MJ et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. *Eur Respir J* 2002; 20: 1378-85.
  61. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. *Chest* 2005; 128: 1936-42.
  62. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. *J Allergy Clin Immunol* 2007; 119: 1055-62.
  63. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. *J Allergy Clin Immunol* 2011; 128: 308-14.
  64. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *N Engl J Med* 2010; 363: 1715-26.
  65. Iwamoto H, Yokoyama A, Shiota N et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. *Eur Respir J* 2008; 31 (6): 1379-80.
  66. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. *Allergy* 2006; 61: 72-8.
  67. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. *Chest* 2010; 138: 1202-12.
  68. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2008; 177: 148-55.
  69. Tintinger GR, Feldman C, Theron AJ et al. Montelukast: more than a cysteinyl leukotriene receptor antagonist? *ScientificWorldJournal* 2010; 10: 2403-13.
  70. Gravett CM, Theron AJ, Steel HC et al. Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. *Eur Respir J* 2010; 36 (6): 1417-24.
  71. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. *N Engl J Med* 2006; 354: 697-708.
  72. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNF $\alpha$ ) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. *Thorax* 2005; 60: 1012-8.
  73. Wenzel SE, Barnes PJ, Bleeker ER, et al. A randomized, double-blind, placebo-controlled study of TNF- $\alpha$  blockade in severe persistent asthma. *Am J Respir Crit Care Med* 2009; 179: 549-58.

74. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. *Lancet*. 2008; 372 (9643): 1107-19.
75. Lotvall J, Akdis CA, Bacharier LB et al., Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011; 127: 355-60.
76. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes *Clin Exp Allergy* 2012 [Epub ahead of print].
77. Moore WC, Meyers D, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. *Am J Respir Crit Care Med* 2010; 181: 315-23.
78. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med* 2008; 178: 218-24.
79. Sutherland ER, Lehman EB, Teodorescu M et al. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. *J Allergy Clin Immunol* 2009; 123 (6): 1328-34.e1.
80. Stenius-Aarniala B, Poussa T, Kvarnström J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. *BMJ* 2000; 320 (7238): 827-32.
81. Dixon AE, Pratley RE, Forgione PM et al Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. *J Allergy Clin Immunol* 2011; 128 (3): 508-15.